Abiraterone Acetate Tablet
Product Images NDC 0378-6920

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 0378-6920). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Abiraterone Acetate Tablets, Usp 250 mg Bottle Label (Image 01)

The label for Abiraterone Acetate film-coated tablets, USP, 500 mg by Mylan Pharmaceuticals Inc. It includes the NDC code 0378-6921-91 and indicates 60 tablets per container. The label specifies the medication is prescription-only, highlights storage instructions, and includes warnings to swallow whole tablets without crushing or chewing.*

FDA Label Image

Abiraterone Acetate Structural Formula (Image 02)

Chemical structure diagram of abiraterone acetate, showing its molecular framework with rings, bonds, and functional groups as part of the compound's structural formula.*

FDA Label Image

Figure 1: Kaplan-meier Overall Survival Curves In Cou-aa-301 (intent-to-treat Analysis) (Image 03)

A Kaplan-Meier survival curve displaying percentage survival over time in months for Abiraterone acetate versus placebo. The x-axis represents time to death in months, and the y-axis shows percent survival. Two curves indicate survival trends for patients treated with Abiraterone acetate and placebo, with sample sizes decreasing over time.*

FDA Label Image

Figure 2: Kaplan Meier Overall Survival Curves In Cou-aa-302 (Image 04)

A Kaplan-Meier survival curve chart depicting the percentage of subjects without death over time in months from randomization. Two groups are compared: one receiving Abiraterone acetate and one receiving placebo. The chart shows survival trends over 60 months with corresponding subject counts at various time points for both groups.*

FDA Label Image

Figure 3: Kaplan Meier Curves Of Radiographic Progression-free Survival In Cou-aa-302 (intent-to-treat Analysis) (Image 05)

A Kaplan-Meier survival curve chart comparing the percentage of subjects without radiographic progression or death over time (months from randomization) between two groups: Abiraterone acetate and Placebo. The x-axis represents months from randomization up to 18 months, and the y-axis shows the percentage of subjects without events, from 0% to 100%. A table below the x-axis lists the number of subjects at risk over time for each group.*

FDA Label Image

Image 06

Label for Abiraterone Acetate tablets, USP, 250 mg film-coated oral tablets by Mylan Pharmaceuticals Inc. The label states 120 tablets per container, includes NDC 0378-6920-78, and a warning that women who are or may be pregnant should not handle the tablets without gloves. The label also instructs storage conditions and cautionary measures.*

FDA Label Image

Image 08

A Kaplan-Meier survival curve showing the percentage of subjects without death over 72 months comparing Abiraterone acetate versus placebo. The x-axis represents months from randomization, and the y-axis shows survival percentage. Abiraterone acetate exhibits higher survival rates than placebo throughout the period, with numbers at risk displayed below the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.